Mesoblast Enters Into Strategic Cardiovascular Alliance for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
77
Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group

NEW YORK and MELBOURNE, Australia, July 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that it has entered into a strategic alliance with one of China’s largest pharmaceutical companies, Tasly Pharmaceutical Group (SHA: 600535; Tasly), for the development, manufacture and commercialization in China of Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction.

Key commercial terms of the strategic alliance are as follows:

  • Tasly will receive exclusive rights and will fund all development, manufacturing and commercialization activities in China for MPC-150-IM and MPC-25-IC.
  • Mesoblast will receive US$40 million (AUD$54 million) on closing, comprising a US$20 million upfront technology access fee and US$20 million in an equity purchase in Mesoblast Limited at $1.86 per share, representing a 20% premium to a blended volume weighted average price calculated over three months, one month and one day.
  • Mesoblast will receive US$25 million on product regulatory approvals in China.
  • Mesoblast will receive double-digit escalating royalties on net product sales.
  • Mesoblast is eligible to receive six escalating milestone payments upon the product candidates reaching certain sales thresholds in China.

In order to potentially expedite development and commercialization of these cardiovascular assets, Tasly and Mesoblast plan to leverage each other’s clinical trial results in China and the United States and other major jurisdictions respectively to support their respective regulatory submissions for MPC-150-IM and MPC-25-IC.

Chairman of Tasly Pharmaceutical Group Mr Yan Kaijing said: "We are very excited to partner with Mesoblast, the premier cellular medicines company, to provide innovative products that have the potential to make a major impact on the high growth cardiovascular market in China.  This aligns well with our corporate strategy to be the lead provider of therapies for patients with cardiovascular conditions in China.”

Mesoblast Chief Executive Dr Silviu Itescu stated: “Tasly Pharmaceutical Group’s powerful combination of clinical, regulatory and manufacturing expertise, together with one of the largest commercial footprints in cardiology in China, makes it the ideal partner for Mesoblast and opens up the China market to our cardiovascular franchise.”

The transaction is subject to governmental approvals from the People’s Republic of China (PRC).

Conference Call Mesoblast will host a conference call to discuss this new strategic alliance on Tuesday July 17, 2018 at 6.30pm EDT; Wednesday, July 18, 2018 at 8.30am AEST.

To access the call, please dial 1 855 881 1339 (U.S.), 1 800 558 698 (Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 783910. The archived webcast will be available on the Investor page of the Company’s website – www.mesoblast.com  

About Tasly Pharmaceutical Group Tasly Pharmaceutical Group (SHA:600535) is one of the largest pharmaceutical companies in China with more than 20 years of operational history. Its business focuses on R&D, manufacturing and commercialization of innovative modern Traditional Chinese Medicine, biologics and chemical drugs in the therapeutic areas of cardiology, metabolism and oncology. Tasly has the only marketed biological product for cardiovascular diseases approved in China. It has one of the largest pharmaceutical sales and marketing teams, including 809 offices established in 29 regions covering all the main therapeutic areas, with a vast distribution network across approximately 20,000 hospitals in China. As of year 2017, its total annual revenues exceeded US$2.5 billion.

About Mesoblast Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward- looking statements include, but are not limited to, statements about: the potential benefits of this alliance and the parties’ ability to maintain the alliance; whether the conditions to the transaction will be satisfied in a timely manner, if at all; the parties’ ability to advance product candidates into, enroll and successfully complete, clinical studies, advance their manufacturing capabilities, and obtain regulatory filings and approvals. There are many uncertainties and risks that may cause our actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information, please contact: Julie Meldrum Corporate Communications T: +61 3 9639 6036 E: julie.meldrum@mesoblast.com    Schond Greenway Investor Relations T: +1 212 880 2060 E: schond.greenway@mesoblast.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 104

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 25

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 103

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 57

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 116

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 33

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Datamars Innovates Textile Sorting with New RFID Sorti-Cart

Updated Category News Views 169

Revolutionizing Textile Management in Retirement Homes Datamars has recently made a significant impact on the textile management industry with the introduction of their innovative UHF Sorti-Cart. This cutting-edge RFID trolley is specially crafted for collecting and sorting soiled textiles in retirement homes, addressing a common issue: the loss of personal garments...

Continue Reading
Investigating Potential Securities Claims for WAL Investors

Updated Category News Views 216

Rosen Law Firm Investigates Securities Claims for WAL Investors The Rosen Law Firm, renowned for protecting investor rights, is currently investigating securities claims concerning Western Alliance Bancorporation (NYSE: WAL). The inquiry roots from reports that the company might have disseminated materially misleading business information to its shareholders. Your Rights...

Continue Reading
Leadership Changes at Marten Transport: A New Chapter Ahead

Updated Category News Views 196

Significant Leadership Transition at Marten Transport Marten Transport, Ltd. (Nasdaq: MRTN) has announced a pivotal leadership change as Timothy Kohl, their esteemed Chief Executive Officer, prepares to retire on September 30, 2025. This transition signifies a new chapter for the company, with Randolph Marten stepping into the roles of Chairman of the Board and Chief...

Continue Reading
Enhancing Global Trade: Made-in-China.com's Sourcing Season

Updated Category News Views 175

Made-in-China.com Launches Golden Sourcing Season Made-in-China.com has unveiled its annual Golden Sourcing Season, an initiative designed to energize global procurement. This exciting event provides international buyers the chance to interact with trusted Chinese suppliers, negotiate competitive deals, and efficiently source a wide array of products. Although this annual...

Continue Reading
Meridian Health Plan Invests $15 Million to Enhance Care Quality

Updated Category News Views 301

Meridian Health Plan Enhances Care Quality with Major Investment Meridian Health Plan of Illinois (NYSE: CNC) is making significant strides in the healthcare industry by investing $15 million into initiatives focused on improving health outcomes. This substantial financial commitment is aimed at enhancing the quality of care provided to over 340,000 Medicaid members...

Continue Reading